Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

Gyorki, David E; Henderson, Michael A

doi:10.5694/mja14.01610

Topics

In reply: We thank Zagarella and colleagues for their comments and the opportunity to correct some misconceptions about the Multicenter Selective Lymphadenectomy Trial-1 study.1

Peter MacCallum Cancer Centre, Melbourne, VIC.

Correspondence: david.gyorki@petermac.org

Competing interests:

No relevant disclosures.

1. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609.
2. Mitra A, Conway C, Walker C, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 2010; 103: 1229-1236.
3. Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol 2009; 27: 5614-5619.

Online responses are no longer available. Please refer to our instructions for authors page for more information.